Zobrazeno 1 - 10
of 21
pro vyhledávání: '"K. A. Narahara"'
Autor:
J N, Cohn, M B, Fowler, M R, Bristow, W S, Colucci, E M, Gilbert, V, Kinhal, S K, Krueger, T, Lejemtel, K A, Narahara, M, Packer, S T, Young, T L, Holcslaw, M A, Lukas
Publikováno v:
Journal of cardiac failure. 3(3)
Many patients remain markedly symptomatic despite optimal current therapy for heart failure. Beta-blockers have often been viewed as contraindicated in this group because of their potential adverse short-term effects on cardiac function.One hundred t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0415c5242e4d049dd0bea74b9ede3bb3
https://pubmed.ncbi.nlm.nih.gov/9330125
https://pubmed.ncbi.nlm.nih.gov/9330125
Autor:
M R, Bristow, E M, Gilbert, W T, Abraham, K F, Adams, M B, Fowler, R E, Hershberger, S H, Kubo, K A, Narahara, H, Ingersoll, S, Krueger, S, Young, N, Shusterman
Publikováno v:
Circulation. 94(11)
We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure.Three hundred forty-five subjects with m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63cebe818a8402f5954300b96874b018
https://pubmed.ncbi.nlm.nih.gov/9355928
https://pubmed.ncbi.nlm.nih.gov/9355928
Autor:
K A, Narahara
Publikováno v:
The American journal of medicine. 95(5)
The spontaneous variation of the left and right ventricular ejection fractions (LVEF and RVEF) was evaluated in patients with chronic heart failure receiving only digoxin and diuretics over a 12-week interval.Fifty-one patients with stable heart fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f639519d108f410f34a1eab21ef2d50d
https://pubmed.ncbi.nlm.nih.gov/8238068
https://pubmed.ncbi.nlm.nih.gov/8238068
Publikováno v:
Journal of the American College of Cardiology. 22(1)
The aim of this study was to assess the efficacy of flosequinan in chronic heart failure.Flosequinan is a new vasodilator drug that acts by interfering with the inositol-triphosphate/protein kinase C pathway, an important mechanism of vasoconstrictio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c52de0fcc7700e6ad6710ec0586601c
https://pubmed.ncbi.nlm.nih.gov/8509565
https://pubmed.ncbi.nlm.nih.gov/8509565
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 34(2)
It is thought that the distribution of 99mTc-sestamibi undergoes minimal change during the first 4 hr after injection. Thus [99mTc] sestamibi unlike 201Tl should not demonstrate significant redistribution in ischemic myocardium. We tested this assump
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56fcec9fdeda1d9c7af0444937888b8f
https://pubmed.ncbi.nlm.nih.gov/8429335
https://pubmed.ncbi.nlm.nih.gov/8429335
Autor:
K A, Narahara
Publikováno v:
American heart journal. 121(5)
In a parallel study design, 164 patients with New York Heart Association Functional class II or III heart failure were randomized to receive either enoximone given as 50 mg three times a day, or 100 mg three times a day, or a matching placebo. All pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::474c0a7af5238e79cac1ac6b34aca689
https://pubmed.ncbi.nlm.nih.gov/1826806
https://pubmed.ncbi.nlm.nih.gov/1826806
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 31(4)
The newly developed technetium-99m (99mTc) isonitriles can be used for the simultaneous evaluation of ventricular function and myocardial perfusion. We compared technetium-99m hexakis-2-methoxy isobutyl isonitrile [( 99mTc] MIBI) derived first-pass l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a0db88c034aa541519e1a4e98b4d4fcc
https://pubmed.ncbi.nlm.nih.gov/2324821
https://pubmed.ncbi.nlm.nih.gov/2324821
Autor:
K A, Narahara
Publikováno v:
The American journal of cardiology. 65(9)
Betaxolol is a new, highly cardioselective, once-a-day beta blocker with a long half-life (mean 16 hours). The antianginal efficacy of 2 doses of betaxolol (20 and 40 mg) given once daily was evaluated and compared with propranolol (40 or 80 mg) 4 ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a83b562bc3fa27142822ebc93537c4f
https://pubmed.ncbi.nlm.nih.gov/2178381
https://pubmed.ncbi.nlm.nih.gov/2178381
Autor:
K. A. Narahara, J. V. Nixon, K. M. Lipscomb, L. L. Burden, T. C. Smitherman, M. C. Hillert, W. Shapiro
Publikováno v:
Clinical Cardiology. 3:309-316
The pathophysiologic basis for the deterioration of patients with stable angina pectoris to unstable angina is unclear. Central to this issue is the question of whether myocardial ischemia occurs at the same or at a lower myocardial oxygen demand dur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0590db7068787bf222a67a0e6aec624
https://doi.org/10.1002/clc.4960030404
https://doi.org/10.1002/clc.4960030404
Publikováno v:
Circulation. 62:1248-1255
To determine whether real-time two-dimensional echocardiography (2-D echo) can estimate the extent of myocardial involvement in patients with acute myocardial infarction (MI), regional wall motion on serial short-axis 2-D echo recordings was analyzed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f10ea96b2464fdf0b8ffbac62276a8
https://doi.org/10.1161/01.cir.62.6.1248
https://doi.org/10.1161/01.cir.62.6.1248